Pierre Vandepapeliere
Directeur Général chez Amyl Therapeutics SRL
Postes actifs de Pierre Vandepapeliere
Sociétés | Poste | Début | Fin |
---|---|---|---|
Amyl Therapeutics SRL
Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Directeur Général | - | - |
Fondateur | - | - |
Historique de carrière de Pierre Vandepapeliere
Anciens postes connus de Pierre Vandepapeliere
Sociétés | Poste | Début | Fin |
---|---|---|---|
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Directeur/Membre du Conseil | - | 07/08/2019 |
Directeur Général | 01/03/2015 | 07/08/2019 | |
Directeur Technique/Scientifique/R&D | 01/03/2015 | 01/11/2019 | |
AstraZeneca, Inc.
AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Corporate Officer/Principal | 31/12/1990 | 31/12/1990 |
ABIVAX | Directeur Technique/Scientifique/R&D | - | - |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Directeur Technique/Scientifique/R&D | 11/11/2009 | - |
Corporate Officer/Principal | - | 11/11/2009 | |
NEOVACS | Directeur Technique/Scientifique/R&D | 09/11/2009 | - |
Formation de Pierre Vandepapeliere
Ghent University | Doctorate Degree |
Facultés Universitaires Notre-Dame de la Paix | Doctorate Degree |
Statistiques
Internationale
Belgique | 6 |
France | 3 |
Etats-Unis | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
NEOVACS | Health Technology |
ABIVAX | Health Technology |
Entreprise privées | 4 |
---|---|
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Health Technology |
AstraZeneca, Inc.
AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Health Technology |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Health Technology |
Amyl Therapeutics SRL
Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Pierre Vandepapeliere
- Expérience